Amplia Communications is a privately owned company headquartered in Trinidad and Tobago. Founded in 2017, the company employs approximately 130 individuals and reported $24.0M in revenue as of 2023. Functioning as a tier 2 media tech buyer, it specializes in providing telecommunications services across the Caribbean.
On March 27, 2026, Amplia reported four new confirmed responses from its combination phase Ib/IIa pancreatic cancer trial. This development followed a significant rise in Amplia's shares on March 22, 2026, which almost doubled after the company announced its pancreatic cancer trial results. Earlier, on February 17, 2026, Amplia initiated two new US sites, the University of California Irvine and The Cleveland Clinic, for its AMPLICITY trial in advanced pancreatic cancer. These US sites were set to commence recruitment activities and joined two existing Australian sites at the Epworth Hospital in Melbourne and Genesis Care in Sydney. Previously, on December 28, 2025, Amplia had reported two ‘complete responders’ in its pancreatic cancer trial.
Similar Companies
Subscribe for full access to Amplia Communications's profile
Amplia Communications offers 4 products in the media and telecoms services industry. Amplia Communications's product portfolio comprises of media and TV services and telecoms.
Subscribe for full access to Amplia Communications's products in full detail
Amplia Communications's revenues were less than $50M in 2023. Caretta Research has split Amplia Communications's revenue into 4 different product categories, the largest of which is enterprise broadband and voice. For full access to Amplia Communications's revenue breakdown subscribe to Caretta Portal.
Subscribe for full access to Amplia Communications's revenue in full detail
Subscribe for full access to Amplia Communications's products in full detail 
